Maina joined us as a partner in 2018, bringing an extensive network and a long track record as a successful healthcare investor.
Prior to joining Sofinnova Partners, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London, where she led and co-led investments in the U.K.
Maina’s interest in biotechnology goes back to childhood. “I've wanted to be in biotech since I was 16 years old,” she said. “It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”
Before turning to investing, Maina worked in the R&D teams of several U.K. and U.S. biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine.
Maina holds a B.S. from the University of Texas at Austin and an MBA from the Imperial Business School. Her current investments include Sitryx Therapeutics, Cincor and Enyo Pharma.